UCP1 and metabolic disease: In summary, the current study demonstrates LETMD1 as a pivotal player in enhancing non-canonical, UCP1-independent energy expenditure in human beige adipocytes, and therefore establishes it as a druggable target for obesity and metabolic diseases.